TG4010 Vaccine Plus Chemo Appears Effective in Advanced NSCLC

Share this content:
TG4010 immunotherapy plus first-line chemotherapy appeared to improve progression-free survival in advanced non-small cell lung cancer.
TG4010 immunotherapy plus first-line chemotherapy appeared to improve progression-free survival in advanced non-small cell lung cancer.

TG4010 immunotherapy plus first-line chemotherapy appeared to improve progression-free survival compared with placebo plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), a study published in the journal The Lancet Oncology has shown.1

The findings of this study are particularly encouraging considering that a phase 2 trial evaluating TG4010 in patients with adenocarcinoma of the prostate was terminated nearly a decade ago.

“The TIME trial results published today support the further development of TG4010 for the treatment of advanced non-small cell lung cancer,” said lead author Elisabeth Quoix, MD, head of the Department of Pulmonology at the University Hospital of Strasbourg in France, and coordinating investigator of the TIME study.2

She emailed Cancer Therapy Advisor that the most important findings were the progression-free survival benefit and the survival benefit obtained for patients, especially adenocarcinoma patients with CD16, CD56, and CD69 triple-positive activated lymphocytes (TrPAL) values in the 3 lowest quartiles.

For the double-blind, placebo-controlled, phase 2b/3 TIME trial, researchers enrolled 222 previously untreated patients with stage 4 NSCLC without a known activating EGFR mutation and with MUC1 expression in at least half of tumoral cells.1

Participants were randomly assigned 1:1 to receive subcutaneous injections of 108 plaque-forming units of TG4010 or placebo from the initiation of chemotherapy every week for 6 weeks, then every 3 weeks until disease progression, unacceptable toxicity, or discontinuation for any reason.

RELATED: Durvalumab Plus Tremelimumab Active in Lung Cancer

The study demonstrated that patients who received TG4010 had a median progression-free survival of 5.9 months (95% CI, 5.4 - 6.7) vs 5.1 months (95% CI, 4.2 - 5.9) for patients who received placebo plus chemotherapy (HR, 0.74; 95% CI, 0.55 - 0.98; P = .019). The platinum-based doublets used were cisplatin-gemcitabine, carboplatin-paclitaxel, and cisplatin-pemetrexed.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters